Central Lab Services/Clinical Trial Lab Services Market by Phase (Phase I, II, III), Service Type (Safety Testing, Immunology), Therapeutic Area (Oncology), Modality (Small Molecules, Vaccine), End user (Pharma & CROs) & Region - Global Forecast to 2030
The global Central lab services/clinical trial lab services market is projected to reach USD 8.18 billion by 2030 from USD 5.97 billion in 2025, at a CAGR of 6.5% during the forecast period.
This is due to increasing adoption of drug discovery, as the adoption increases the demand for these services rises. Additionally, increasing government support to provide grants for healthcare is increasing, thus rising the number of clinical trials, consequently increasing the demand for the central lab clinical service trial. However, the high cost associated with the clinical trial methods are the major restraint to the market. Additionally, the shortage of trained healthcare professionals & limited knowledge about the services is major challenge for the market growth. But is creating a conducive environment for market expansion over the forecast period of 2025-2030.
“The pharmaceutical & biopharmaceutical companies segment of central lab services/clinical trial lab services market by end user to hold largest position forecast period.”
Based on the end user, the central lab services/clinical trial lab services market is divided into pharmaceutical & biopharmaceutical companies, CROS, medical device companies, and other end users. Among these, in 2024 pharmaceutical & biopharmaceutical companie segment account for the largest market share of 61.8% in central lab services/clinical trial lab services market. This is due to the rising prevalence of rare disease. Majority of the pharmaceutical companies are conducting the clinical trials for the cure of such diseases via advanced technologies. Thus, majority of the companies prefer these services. Thus, as the prevalence of these diseases is increasing the need for long term treatment is rising, consequently increasing the demand for central lab services/clinical trial lab services market.
“The oncology segment accounts for the largest market share in central lab services/clinical trial lab services market.”
Based on theraprutic area, the central lab services/clinical trial lab services market is segmented into oncology, infectious diseases, neurology, cardiology, and other therapeutic areas. The oncology segment holds for the largest market share in central lab services/clinical trial lab services market due to increasing number of cancer patients. Oncology clinical trials often require modern diagnostic testing, including biomarker testing, genomic testing, and tumor profiling, to assess the effectiveness and safety of new cancer therapies in clinical trials. Central labs are important in providing these services, ensuring that testing is viable, consistent, and compliant with regulatory standards across multiple sites. With the rising focus on precision medicine, the need for specialized and high-quality lab testing in oncology is significant, making the oncology segment the largest and most critical in the central lab services market.
“Asia Pacific is the fastest growing region of the central lab services/clinical trial lab services market by region.”
The global central lab services/clinical trial lab services market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the fastest growing regional market for entral lab services/clinical trial lab services and is estimated to grow at the highest CAGR during the forecast period. This is due to increasing prevalence of rare diseases and rising population across the region. Asia Pacific region includes Japan, China, India, and Rest of Asia Pacific. Among these, China accounts for the largest market share in central lab services/clinical trial lab services market in 2024. This is due to its rapid expansion of pharmaceutical and biotechnology industries, added with the with a large patient population and increasing demand for innovative treatments. The country's growing healthcare infrastructure, investment in clinical research, and supportive regulatory environment have made it an attractive hub for global clinical trials.
A breakdown of the primary participants referred to for this report is provided below:
Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.
Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
The major players operating in the central lab services/clinical trial lab services market are Thermo Fisher Scientific Inc. (US), IQVIA (US), ICON plc (Ireland), Labcorp (US), Quest Diagnostics (US), Charles River Laboratories (US), Medpace (US), Frontage lab (US), SGS Sociйtй Gйnйrale de Surveillance SA (Switzerland), Eurofins Scientific (Luxembourg), and REPROCELL Inc. (Japan).
Research Coverage
This report studies the central lab services/clinical trial lab services market based on product, type, end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.
This report provides insights on the following pointers:
This is due to increasing adoption of drug discovery, as the adoption increases the demand for these services rises. Additionally, increasing government support to provide grants for healthcare is increasing, thus rising the number of clinical trials, consequently increasing the demand for the central lab clinical service trial. However, the high cost associated with the clinical trial methods are the major restraint to the market. Additionally, the shortage of trained healthcare professionals & limited knowledge about the services is major challenge for the market growth. But is creating a conducive environment for market expansion over the forecast period of 2025-2030.
“The pharmaceutical & biopharmaceutical companies segment of central lab services/clinical trial lab services market by end user to hold largest position forecast period.”
Based on the end user, the central lab services/clinical trial lab services market is divided into pharmaceutical & biopharmaceutical companies, CROS, medical device companies, and other end users. Among these, in 2024 pharmaceutical & biopharmaceutical companie segment account for the largest market share of 61.8% in central lab services/clinical trial lab services market. This is due to the rising prevalence of rare disease. Majority of the pharmaceutical companies are conducting the clinical trials for the cure of such diseases via advanced technologies. Thus, majority of the companies prefer these services. Thus, as the prevalence of these diseases is increasing the need for long term treatment is rising, consequently increasing the demand for central lab services/clinical trial lab services market.
“The oncology segment accounts for the largest market share in central lab services/clinical trial lab services market.”
Based on theraprutic area, the central lab services/clinical trial lab services market is segmented into oncology, infectious diseases, neurology, cardiology, and other therapeutic areas. The oncology segment holds for the largest market share in central lab services/clinical trial lab services market due to increasing number of cancer patients. Oncology clinical trials often require modern diagnostic testing, including biomarker testing, genomic testing, and tumor profiling, to assess the effectiveness and safety of new cancer therapies in clinical trials. Central labs are important in providing these services, ensuring that testing is viable, consistent, and compliant with regulatory standards across multiple sites. With the rising focus on precision medicine, the need for specialized and high-quality lab testing in oncology is significant, making the oncology segment the largest and most critical in the central lab services market.
“Asia Pacific is the fastest growing region of the central lab services/clinical trial lab services market by region.”
The global central lab services/clinical trial lab services market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the fastest growing regional market for entral lab services/clinical trial lab services and is estimated to grow at the highest CAGR during the forecast period. This is due to increasing prevalence of rare diseases and rising population across the region. Asia Pacific region includes Japan, China, India, and Rest of Asia Pacific. Among these, China accounts for the largest market share in central lab services/clinical trial lab services market in 2024. This is due to its rapid expansion of pharmaceutical and biotechnology industries, added with the with a large patient population and increasing demand for innovative treatments. The country's growing healthcare infrastructure, investment in clinical research, and supportive regulatory environment have made it an attractive hub for global clinical trials.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%
- By Designation: C-level–25%, Director-level–30% and Others–45%
- By Region: North America–40%, Europe–25%, Asia Pacific–20%, Latin America- 10%, and Middle east and Africa – 5%
Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.
Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
The major players operating in the central lab services/clinical trial lab services market are Thermo Fisher Scientific Inc. (US), IQVIA (US), ICON plc (Ireland), Labcorp (US), Quest Diagnostics (US), Charles River Laboratories (US), Medpace (US), Frontage lab (US), SGS Sociйtй Gйnйrale de Surveillance SA (Switzerland), Eurofins Scientific (Luxembourg), and REPROCELL Inc. (Japan).
Research Coverage
This report studies the central lab services/clinical trial lab services market based on product, type, end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.
This report provides insights on the following pointers:
- Analysis of Key divers (Increasing number of clinical trials, increasing investments in research & development, growing prevalence of rare diseases), restraints (High cost associated with clinicaltrials, Shortage of skilled professionals), opportunity (Emerging markets worldwide, decentralized and virtual clinical trials), Challenge (regulatory complexities, limited patient diversity and cybersecurity or intellectual property concerns)
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the central lab services/clinical trial lab services market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the central lab services/clinical trial lab services market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the pain management devices market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key industry insights
2.1.2.3 Key data from primary sources
2.1.2.4 Breakdown of primary interviews
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
2.2.1.2 Approach 2: Presentations of companies and primary interviews
2.2.1.3 Approach 3: Primary interviews
2.2.1.4 Growth forecast
2.2.1.5 CAGR projections
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.4.1 STUDY-RELATED ASSUMPTIONS
2.4.2 PARAMETRIC ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
2.6 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET OVERVIEW
4.2 ASIA PACIFIC CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER AND COUNTRY
4.3 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY COUNTRY
4.4 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, REGIONAL MIX, 2025 VS. 2030
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing number of clinical trials
5.2.1.2 Rising investments in research & development
5.2.1.3 Growing prevalence of rare diseases
5.2.1.4 Favorable government initiatives
5.2.2 RESTRAINTS
5.2.2.1 High costs associated with clinical trials
5.2.2.2 Shortage of skilled professionals
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets worldwide
5.2.3.2 Decentralized and virtual clinical trials
5.2.4 CHALLENGES
5.2.4.1 Regulatory complexities
5.2.4.2 Limited patient diversity
5.2.4.3 Cybersecurity and intellectual property concerns
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 VALUE CHAIN ANALYSIS
5.4.1 RESOURCE ACQUISITION AND PREPARATION
5.4.2 CLINICAL TRIAL EXECUTION
5.4.3 DATA REPORTING AND RESULT SUBMISSION
5.4.4 PROMOTION AND REGULATORY FILING
5.5 ECOSYSTEM ANALYSIS
5.6 INVESTMENT AND FUNDING SCENARIO
5.7 TECHNOLOGY ANALYSIS
5.7.1 KEY TECHNOLOGIES
5.7.1.1 Enzyme-linked immunosorbent assay
5.7.2 ADJACENT TECHNOLOGIES
5.7.2.1 Next-generation sequencing
5.8 KEY CONFERENCES AND EVENTS, 2025–2026
5.9 CASE STUDY ANALYSIS
5.9.1 PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY AND SAFETY OF TWO COMBINATION THERAPIES (CERBA RESEARCH)
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY FRAMEWORK
5.10.1.1 North America
5.10.1.2 Europe
5.10.1.3 Asia Pacific
5.10.1.4 Rest of the World
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF SUPPLIERS
5.11.4 BARGAINING POWER OF BUYERS
5.11.5 INTENSITY OF COMPETITIVE RIVALRY
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.12.2 BUYING CRITERIA
5.13 IMPACT OF AI/GENERATIVE AI ON CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET
5.13.1 INTRODUCTION
5.13.2 MARKET POTENTIAL OF CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES
5.13.3 AI USE CASES
5.13.4 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL LAB ECOSYSTEM
6 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE
6.1 INTRODUCTION
6.2 PHASE I
6.2.1 NEED TO ASSESS SAFETY, DOSAGE, AND POTENTIAL SIDE EFFECTS OF DRUGS TO AID GROWTH
6.3 PHASE II
6.3.1 NEED TO EVALUATE DESIRED EFFECT AND ADDITIONAL SAFETY DATA OF DRUGS TO DRIVE MARKET
6.4 PHASE III
6.4.1 RISING INCLINATION TOWARD CONFIRMING SAFETY AND EFFICACY OF DRUGS TO BOOST MARKET
6.5 PHASE IV
6.5.1 ONGOING SAFETY SURVEILLANCE ON DRUG TRIALS TO AUGMENT GROWTH
7 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY SERVICE TYPE
7.1 INTRODUCTION
7.2 SAFETY TESTING
7.2.1 NEED TO ENSURE COMPLIANCE WITH SAFETY STANDARDS TO PROMOTE GROWTH
7.3 IMMUNOLOGY
7.3.1 INCREASING FOCUS ON IMMUNOTHERAPIES TO STIMULATE GROWTH
7.4 GENETIC TESTING
7.4.1 GROWING ADVANCEMENTS IN NEXT-GENERATION SEQUENCING TO DRIVE MARKET
7.5 COAGULATION TESTING
7.5.1 ESSENTIAL ROLE IN MONITORING COAGULATION DISORDERS AND EVALUATING ANTICOAGULANT THERAPIES TO EXPEDITE GROWTH
7.6 PATHOLOGY TESTING
7.6.1 ABILITY TO PROVIDE INSIGHTS INTO DISEASE MECHANISMS, TREATMENT EFFECTS, AND DIAGNOSTICS TO AID GROWTH
7.7 BIOMARKERS
7.7.1 NEED TO EXAMINE TEST EFFECTS ON PATIENTS TO AUGMENT GROWTH
7.8 COMPANION DIAGNOSTICS
7.8.1 GROWING INCLINATION TOWARD PERSONALIZED TREATMENTS TO DRIVE MARKET
7.9 OTHER TESTS
8 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY THERAPEUTIC AREA
8.1 INTRODUCTION
8.2 ONCOLOGY
8.2.1 INCREASING CANCER RESEARCH STUDIES TO ACCELERATE GROWTH
8.3 INFECTIOUS DISEASES
8.3.1 INCREASING CASES OF INFECTIOUS DISEASES TO ENCOURAGE GROWTH
8.4 NEUROLOGY
8.4.1 RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO FACILITATE GROWTH
8.5 CARDIOLOGY
8.5.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES TO PROPEL MARKET
8.6 OTHER THERAPEUTIC AREAS
9 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY MODALITY
9.1 INTRODUCTION
9.2 SMALL MOLECULES
9.2.1 EMERGENCE OF THERAPEUTIC MODALITIES TO AMPLIFY GROWTH
9.3 BIOLOGICS
9.3.1 MONOCLONAL ANTIBODIES
9.3.1.1 Growing advancements in antibody engineering to drive market
9.3.2 VACCINES
9.3.2.1 Increasing investments in vaccine development to favor growth
9.3.3 OTHER THERAPEUTIC PRODUCTS
9.4 CELL & GENE THERAPY
9.4.1 OUTSOURCING TREND TO FAVOR GROWTH
9.5 MEDICAL DEVICES & IVD DEVICES
9.5.1 RISING FOCUS ON REAL-TIME PATIENT HEALTH TRACKING TO BOOST MARKET
10 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER
10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
10.2.1 EMERGING BIOPHARMA COMPANIES TO EXPEDITE GROWTH
10.3 CLINICAL RESEARCH ORGANIZATIONS
10.3.1 CRITICAL ROLE IN SITE SELECTION, RECRUITMENT SUPPORT, CLINICAL MONITORING, AND DATA COLLECTION TO DRIVE MARKET
10.4 MEDICAL DEVICE COMPANIES
10.4.1 RISING FOCUS ON QUALITY AND SAFETY STANDARDS TO STIMULATE GROWTH
10.5 OTHER END USERS
11 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 Increasing clinical trials to support growth
11.2.3 CANADA
11.2.3.1 Rising incidence of chronic diseases to advance growth
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 Increasing healthcare expenditure to intensify growth
11.3.3 FRANCE
11.3.3.1 Growing investments in life sciences sector to boost market
11.3.4 UK
11.3.4.1 High number of oncology clinical trials to facilitate growth
11.3.5 ITALY
11.3.5.1 Rising focus on streamlining clinical trial process to expedite growth
11.3.6 SPAIN
11.3.6.1 Emerging biotech companies to bolster growth
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 JAPAN
11.4.2.1 Growing demand for drug development to propel market
11.4.3 CHINA
11.4.3.1 Booming pharmaceutical industry to drive market
11.4.4 INDIA
11.4.4.1 Increasing regulatory reforms to foster growth
11.4.5 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 ROBUST MANUFACTURING INFRASTRUCTURE TO SUSTAIN GROWTH
11.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 GROWING DEMAND FOR OUTSOURCING SERVICES TO FUEL MARKET
11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET
12.3 REVENUE ANALYSIS, 2020?2024
12.4 MARKET SHARE ANALYSIS, 2024
12.5 COMPANY VALUATION AND FINANCIAL METRICS
12.6 BRAND/PRODUCT COMPARISON
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.7.1 STARS
12.7.2 EMERGING LEADERS
12.7.3 PERVASIVE PLAYERS
12.7.4 PARTICIPANTS
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.7.5.1 Company footprint
12.7.5.2 Region footprint
12.7.5.3 Product type footprint
12.7.5.4 Therapeutic area footprint
12.7.5.5 Phase footprint
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.8.1 PROGRESSIVE COMPANIES
12.8.2 RESPONSIVE COMPANIES
12.8.3 DYNAMIC COMPANIES
12.8.4 STARTING BLOCKS
12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
12.8.5.1 Detailed list of key startups/SMEs
12.8.5.2 Competitive benchmarking of key startups/SMEs
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES
12.9.2 DEALS
12.9.3 EXPANSIONS
12.9.4 OTHER DEVELOPMENTS
13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 THERMO FISHER SCIENTIFIC INC.
13.1.1.1 Business overview
13.1.1.2 Products/Services offered
13.1.1.3 Recent developments
13.1.1.3.1 Product launches
13.1.1.3.2 Deals
13.1.1.3.3 Expansions
13.1.1.4 MnM view
13.1.1.4.1 Key strengths
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses and competitive threats
13.1.2 IQVIA
13.1.2.1 Business overview
13.1.2.2 Products/Services offered
13.1.2.3 Recent developments
13.1.2.3.1 Product launches
13.1.2.3.2 Deals
13.1.2.4 MnM view
13.1.2.4.1 Right to win
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses and competitive threats
13.1.3 ICON PLC
13.1.3.1 Business overview
13.1.3.2 Products/Services offered
13.1.3.3 Recent developments
13.1.3.3.1 Product launches
13.1.3.3.2 Deals
13.1.3.4 MnM view
13.1.3.4.1 Right to win
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses and competitive threats
13.1.4 CHARLES RIVER LABORATORIES
13.1.4.1 Business overview
13.1.4.2 Products/Services offered
13.1.4.3 Recent developments
13.1.4.3.1 Deals
13.1.4.3.2 Expansions
13.1.4.4 MnM view
13.1.4.4.1 Right to win
13.1.4.4.2 Strategic choices
13.1.4.4.3 Weaknesses and competitive threats
13.1.5 LABCORP
13.1.5.1 Business overview
13.1.5.2 Products/Services offered
13.1.5.3 Recent developments
13.1.5.3.1 Product launches
13.1.5.3.2 Deals
13.1.5.3.3 Expansions
13.1.5.3.4 Other developments
13.1.5.4 MnM view
13.1.5.4.1 Key strengths
13.1.5.4.2 Strategic choices
13.1.5.4.3 Weaknesses and competitive threats
13.1.6 QUEST DIAGNOSTICS
13.1.6.1 Business overview
13.1.6.2 Products/Services offered
13.1.6.3 Recent developments
13.1.6.3.1 Deals
13.1.7 MEDPACE
13.1.7.1 Business overview
13.1.7.2 Products/Services offered
13.1.7.3 Recent developments
13.1.7.3.1 Expansions
13.1.8 FRONTAGE LABS
13.1.8.1 Business overview
13.1.8.2 Products/Services offered
13.1.9 SGS SOCIЙTЙ GЙNЙRALE DE SURVEILLANCE SA
13.1.9.1 Business overview
13.1.9.2 Products/Services offered
13.1.9.3 Recent developments
13.1.9.3.1 Deals
13.1.10 EUROFINS SCIENTIFIC
13.1.10.1 Business overview
13.1.10.2 Products/Services offered
13.1.10.3 Recent developments
13.1.10.3.1 Deals
13.1.11 REPROCELL INC.
13.1.11.1 Business overview
13.1.11.2 Products/Services offered
13.1.11.3 Recent developments
13.1.11.3.1 Deals
13.1.12 ACM GLOBAL LABORATORIES
13.1.12.1 Business overview
13.1.12.2 Products/Services offered
13.1.12.3 Recent developments
13.1.12.3.1 Deals
13.2 OTHER PLAYERS
13.2.1 WORLDWIDE CLINICAL TRIALS
13.2.2 VERSITI
13.2.3 CTI CLINICAL TRIAL & CONSULTING
13.2.4 CLARITY LABORATORIES, INC
13.2.5 NOVOTECH
13.2.6 ARUP LABORATORIES
13.2.7 PRECISION MEDICINE GROUP
13.2.8 BIOAGILYTIX LABS
13.2.9 CERBA HEALTHCARE
13.2.10 ALMAC GROUP
13.2.11 MLM MEDICAL LABS
13.2.12 SALVUS BIORESEARCH SOLUTIONS LLP
13.2.13 UNILABS
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key industry insights
2.1.2.3 Key data from primary sources
2.1.2.4 Breakdown of primary interviews
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
2.2.1.2 Approach 2: Presentations of companies and primary interviews
2.2.1.3 Approach 3: Primary interviews
2.2.1.4 Growth forecast
2.2.1.5 CAGR projections
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.4.1 STUDY-RELATED ASSUMPTIONS
2.4.2 PARAMETRIC ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
2.6 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET OVERVIEW
4.2 ASIA PACIFIC CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER AND COUNTRY
4.3 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY COUNTRY
4.4 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, REGIONAL MIX, 2025 VS. 2030
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing number of clinical trials
5.2.1.2 Rising investments in research & development
5.2.1.3 Growing prevalence of rare diseases
5.2.1.4 Favorable government initiatives
5.2.2 RESTRAINTS
5.2.2.1 High costs associated with clinical trials
5.2.2.2 Shortage of skilled professionals
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets worldwide
5.2.3.2 Decentralized and virtual clinical trials
5.2.4 CHALLENGES
5.2.4.1 Regulatory complexities
5.2.4.2 Limited patient diversity
5.2.4.3 Cybersecurity and intellectual property concerns
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 VALUE CHAIN ANALYSIS
5.4.1 RESOURCE ACQUISITION AND PREPARATION
5.4.2 CLINICAL TRIAL EXECUTION
5.4.3 DATA REPORTING AND RESULT SUBMISSION
5.4.4 PROMOTION AND REGULATORY FILING
5.5 ECOSYSTEM ANALYSIS
5.6 INVESTMENT AND FUNDING SCENARIO
5.7 TECHNOLOGY ANALYSIS
5.7.1 KEY TECHNOLOGIES
5.7.1.1 Enzyme-linked immunosorbent assay
5.7.2 ADJACENT TECHNOLOGIES
5.7.2.1 Next-generation sequencing
5.8 KEY CONFERENCES AND EVENTS, 2025–2026
5.9 CASE STUDY ANALYSIS
5.9.1 PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY AND SAFETY OF TWO COMBINATION THERAPIES (CERBA RESEARCH)
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY FRAMEWORK
5.10.1.1 North America
5.10.1.2 Europe
5.10.1.3 Asia Pacific
5.10.1.4 Rest of the World
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF SUPPLIERS
5.11.4 BARGAINING POWER OF BUYERS
5.11.5 INTENSITY OF COMPETITIVE RIVALRY
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.12.2 BUYING CRITERIA
5.13 IMPACT OF AI/GENERATIVE AI ON CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET
5.13.1 INTRODUCTION
5.13.2 MARKET POTENTIAL OF CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES
5.13.3 AI USE CASES
5.13.4 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL LAB ECOSYSTEM
6 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE
6.1 INTRODUCTION
6.2 PHASE I
6.2.1 NEED TO ASSESS SAFETY, DOSAGE, AND POTENTIAL SIDE EFFECTS OF DRUGS TO AID GROWTH
6.3 PHASE II
6.3.1 NEED TO EVALUATE DESIRED EFFECT AND ADDITIONAL SAFETY DATA OF DRUGS TO DRIVE MARKET
6.4 PHASE III
6.4.1 RISING INCLINATION TOWARD CONFIRMING SAFETY AND EFFICACY OF DRUGS TO BOOST MARKET
6.5 PHASE IV
6.5.1 ONGOING SAFETY SURVEILLANCE ON DRUG TRIALS TO AUGMENT GROWTH
7 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY SERVICE TYPE
7.1 INTRODUCTION
7.2 SAFETY TESTING
7.2.1 NEED TO ENSURE COMPLIANCE WITH SAFETY STANDARDS TO PROMOTE GROWTH
7.3 IMMUNOLOGY
7.3.1 INCREASING FOCUS ON IMMUNOTHERAPIES TO STIMULATE GROWTH
7.4 GENETIC TESTING
7.4.1 GROWING ADVANCEMENTS IN NEXT-GENERATION SEQUENCING TO DRIVE MARKET
7.5 COAGULATION TESTING
7.5.1 ESSENTIAL ROLE IN MONITORING COAGULATION DISORDERS AND EVALUATING ANTICOAGULANT THERAPIES TO EXPEDITE GROWTH
7.6 PATHOLOGY TESTING
7.6.1 ABILITY TO PROVIDE INSIGHTS INTO DISEASE MECHANISMS, TREATMENT EFFECTS, AND DIAGNOSTICS TO AID GROWTH
7.7 BIOMARKERS
7.7.1 NEED TO EXAMINE TEST EFFECTS ON PATIENTS TO AUGMENT GROWTH
7.8 COMPANION DIAGNOSTICS
7.8.1 GROWING INCLINATION TOWARD PERSONALIZED TREATMENTS TO DRIVE MARKET
7.9 OTHER TESTS
8 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY THERAPEUTIC AREA
8.1 INTRODUCTION
8.2 ONCOLOGY
8.2.1 INCREASING CANCER RESEARCH STUDIES TO ACCELERATE GROWTH
8.3 INFECTIOUS DISEASES
8.3.1 INCREASING CASES OF INFECTIOUS DISEASES TO ENCOURAGE GROWTH
8.4 NEUROLOGY
8.4.1 RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO FACILITATE GROWTH
8.5 CARDIOLOGY
8.5.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES TO PROPEL MARKET
8.6 OTHER THERAPEUTIC AREAS
9 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY MODALITY
9.1 INTRODUCTION
9.2 SMALL MOLECULES
9.2.1 EMERGENCE OF THERAPEUTIC MODALITIES TO AMPLIFY GROWTH
9.3 BIOLOGICS
9.3.1 MONOCLONAL ANTIBODIES
9.3.1.1 Growing advancements in antibody engineering to drive market
9.3.2 VACCINES
9.3.2.1 Increasing investments in vaccine development to favor growth
9.3.3 OTHER THERAPEUTIC PRODUCTS
9.4 CELL & GENE THERAPY
9.4.1 OUTSOURCING TREND TO FAVOR GROWTH
9.5 MEDICAL DEVICES & IVD DEVICES
9.5.1 RISING FOCUS ON REAL-TIME PATIENT HEALTH TRACKING TO BOOST MARKET
10 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY END USER
10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
10.2.1 EMERGING BIOPHARMA COMPANIES TO EXPEDITE GROWTH
10.3 CLINICAL RESEARCH ORGANIZATIONS
10.3.1 CRITICAL ROLE IN SITE SELECTION, RECRUITMENT SUPPORT, CLINICAL MONITORING, AND DATA COLLECTION TO DRIVE MARKET
10.4 MEDICAL DEVICE COMPANIES
10.4.1 RISING FOCUS ON QUALITY AND SAFETY STANDARDS TO STIMULATE GROWTH
10.5 OTHER END USERS
11 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET,
BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 Increasing clinical trials to support growth
11.2.3 CANADA
11.2.3.1 Rising incidence of chronic diseases to advance growth
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 Increasing healthcare expenditure to intensify growth
11.3.3 FRANCE
11.3.3.1 Growing investments in life sciences sector to boost market
11.3.4 UK
11.3.4.1 High number of oncology clinical trials to facilitate growth
11.3.5 ITALY
11.3.5.1 Rising focus on streamlining clinical trial process to expedite growth
11.3.6 SPAIN
11.3.6.1 Emerging biotech companies to bolster growth
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 JAPAN
11.4.2.1 Growing demand for drug development to propel market
11.4.3 CHINA
11.4.3.1 Booming pharmaceutical industry to drive market
11.4.4 INDIA
11.4.4.1 Increasing regulatory reforms to foster growth
11.4.5 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 ROBUST MANUFACTURING INFRASTRUCTURE TO SUSTAIN GROWTH
11.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 GROWING DEMAND FOR OUTSOURCING SERVICES TO FUEL MARKET
11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET
12.3 REVENUE ANALYSIS, 2020?2024
12.4 MARKET SHARE ANALYSIS, 2024
12.5 COMPANY VALUATION AND FINANCIAL METRICS
12.6 BRAND/PRODUCT COMPARISON
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.7.1 STARS
12.7.2 EMERGING LEADERS
12.7.3 PERVASIVE PLAYERS
12.7.4 PARTICIPANTS
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.7.5.1 Company footprint
12.7.5.2 Region footprint
12.7.5.3 Product type footprint
12.7.5.4 Therapeutic area footprint
12.7.5.5 Phase footprint
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.8.1 PROGRESSIVE COMPANIES
12.8.2 RESPONSIVE COMPANIES
12.8.3 DYNAMIC COMPANIES
12.8.4 STARTING BLOCKS
12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
12.8.5.1 Detailed list of key startups/SMEs
12.8.5.2 Competitive benchmarking of key startups/SMEs
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES
12.9.2 DEALS
12.9.3 EXPANSIONS
12.9.4 OTHER DEVELOPMENTS
13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 THERMO FISHER SCIENTIFIC INC.
13.1.1.1 Business overview
13.1.1.2 Products/Services offered
13.1.1.3 Recent developments
13.1.1.3.1 Product launches
13.1.1.3.2 Deals
13.1.1.3.3 Expansions
13.1.1.4 MnM view
13.1.1.4.1 Key strengths
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses and competitive threats
13.1.2 IQVIA
13.1.2.1 Business overview
13.1.2.2 Products/Services offered
13.1.2.3 Recent developments
13.1.2.3.1 Product launches
13.1.2.3.2 Deals
13.1.2.4 MnM view
13.1.2.4.1 Right to win
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses and competitive threats
13.1.3 ICON PLC
13.1.3.1 Business overview
13.1.3.2 Products/Services offered
13.1.3.3 Recent developments
13.1.3.3.1 Product launches
13.1.3.3.2 Deals
13.1.3.4 MnM view
13.1.3.4.1 Right to win
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses and competitive threats
13.1.4 CHARLES RIVER LABORATORIES
13.1.4.1 Business overview
13.1.4.2 Products/Services offered
13.1.4.3 Recent developments
13.1.4.3.1 Deals
13.1.4.3.2 Expansions
13.1.4.4 MnM view
13.1.4.4.1 Right to win
13.1.4.4.2 Strategic choices
13.1.4.4.3 Weaknesses and competitive threats
13.1.5 LABCORP
13.1.5.1 Business overview
13.1.5.2 Products/Services offered
13.1.5.3 Recent developments
13.1.5.3.1 Product launches
13.1.5.3.2 Deals
13.1.5.3.3 Expansions
13.1.5.3.4 Other developments
13.1.5.4 MnM view
13.1.5.4.1 Key strengths
13.1.5.4.2 Strategic choices
13.1.5.4.3 Weaknesses and competitive threats
13.1.6 QUEST DIAGNOSTICS
13.1.6.1 Business overview
13.1.6.2 Products/Services offered
13.1.6.3 Recent developments
13.1.6.3.1 Deals
13.1.7 MEDPACE
13.1.7.1 Business overview
13.1.7.2 Products/Services offered
13.1.7.3 Recent developments
13.1.7.3.1 Expansions
13.1.8 FRONTAGE LABS
13.1.8.1 Business overview
13.1.8.2 Products/Services offered
13.1.9 SGS SOCIЙTЙ GЙNЙRALE DE SURVEILLANCE SA
13.1.9.1 Business overview
13.1.9.2 Products/Services offered
13.1.9.3 Recent developments
13.1.9.3.1 Deals
13.1.10 EUROFINS SCIENTIFIC
13.1.10.1 Business overview
13.1.10.2 Products/Services offered
13.1.10.3 Recent developments
13.1.10.3.1 Deals
13.1.11 REPROCELL INC.
13.1.11.1 Business overview
13.1.11.2 Products/Services offered
13.1.11.3 Recent developments
13.1.11.3.1 Deals
13.1.12 ACM GLOBAL LABORATORIES
13.1.12.1 Business overview
13.1.12.2 Products/Services offered
13.1.12.3 Recent developments
13.1.12.3.1 Deals
13.2 OTHER PLAYERS
13.2.1 WORLDWIDE CLINICAL TRIALS
13.2.2 VERSITI
13.2.3 CTI CLINICAL TRIAL & CONSULTING
13.2.4 CLARITY LABORATORIES, INC
13.2.5 NOVOTECH
13.2.6 ARUP LABORATORIES
13.2.7 PRECISION MEDICINE GROUP
13.2.8 BIOAGILYTIX LABS
13.2.9 CERBA HEALTHCARE
13.2.10 ALMAC GROUP
13.2.11 MLM MEDICAL LABS
13.2.12 SALVUS BIORESEARCH SOLUTIONS LLP
13.2.13 UNILABS
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
